Analyst Ratings for Acrivon Therapeutics
Portfolio Pulse from Benzinga Insights
Acrivon Therapeutics (NASDAQ:ACRV) received 4 analyst ratings in the last quarter, with 3 bullish and 1 somewhat bullish, and no indifferent, somewhat bearish, or bearish ratings. The average price target is $23.5, which is significantly higher than the current price of $5.4, suggesting a substantial upside. However, this target is a 6.0% decrease from the previous target of $25.00. Analysts rate stocks typically once a quarter and provide insights into company performance.
November 10, 2023 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Acrivon Therapeutics has received positive ratings from analysts, with an average price target of $23.5, indicating a potential significant upside from the current price of $5.4.
The unanimous bullish and somewhat bullish ratings from analysts suggest a strong confidence in Acrivon Therapeutics' potential growth. The substantial difference between the current price and the target price indicates a high upside potential, which is likely to positively influence investor sentiment and the stock price in the short term. The slight decrease in the target price may slightly temper expectations but does not significantly detract from the overall positive outlook.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100